We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Read MoreHide Full Article
Key Takeaways
Pfizer's oncology segment is expected to post $4 billion in Q2 sales.
PFE's ADC products show mixed trends, with Padcev sales rising and Adcetris hit by U.S. competition.
Ibrance sales likely declined due to competition, generics and IRA-driven pricing pressure.
Pfizer (PFE - Free Report) is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s total revenues, growing 7% year over year. Investors will be closely watching this segment when Pfizer reports second-quarter results on Aug. 5.
Within the oncology unit, sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased during the quarter. However, sales of key medicine Ibrance are expected to have been hurt due to continued competitive pressure across markets, generic entry and the Inflation Reduction Act ("IRA") impact in the United States.
With regard to ADC products, competitive pressure in the United States is likely to have hurt sales of Adcetris, while strong demand trends must have benefited Padcev’s sales.
Our model estimates for second-quarter 2025 sales of the overall oncology segment are pegged at $4.0 billion, implying a 2% rise year over year.
Beyond oncology, Pfizer’s top line is likely to have been aided by its key in-line products like Vyndaqel and Eliquis, alongside newer additions like Nurtec. However, this growth is expected to have been offset by the U.S. Medicare Part D headwinds and the continued declining sales of its COVID-19 products.
For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 46% of Merck’s total revenues in the first quarter of 2025.
PFE’s Price Performance, Valuation and Estimates
Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.25 times forward earnings, lower than 15.12 for the industry and the stock’s 5-year mean of 10.86.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has declined from $3.08 to $3.05, while that for 2026 has gone up from $3.08 to $3.09 over the past 60 days.
Image: Bigstock
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Key Takeaways
Pfizer (PFE - Free Report) is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s total revenues, growing 7% year over year. Investors will be closely watching this segment when Pfizer reports second-quarter results on Aug. 5.
Within the oncology unit, sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased during the quarter. However, sales of key medicine Ibrance are expected to have been hurt due to continued competitive pressure across markets, generic entry and the Inflation Reduction Act ("IRA") impact in the United States.
With regard to ADC products, competitive pressure in the United States is likely to have hurt sales of Adcetris, while strong demand trends must have benefited Padcev’s sales.
Our model estimates for second-quarter 2025 sales of the overall oncology segment are pegged at $4.0 billion, implying a 2% rise year over year.
Beyond oncology, Pfizer’s top line is likely to have been aided by its key in-line products like Vyndaqel and Eliquis, alongside newer additions like Nurtec. However, this growth is expected to have been offset by the U.S. Medicare Part D headwinds and the continued declining sales of its COVID-19 products.
Competition in the Oncology Space
Other large players in the oncology space are AstraZeneca (AZN - Free Report) and Merck (MRK - Free Report) .
For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 46% of Merck’s total revenues in the first quarter of 2025.
PFE’s Price Performance, Valuation and Estimates
Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.25 times forward earnings, lower than 15.12 for the industry and the stock’s 5-year mean of 10.86.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has declined from $3.08 to $3.05, while that for 2026 has gone up from $3.08 to $3.09 over the past 60 days.
Image Source: Zacks Investment Research
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.